| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Like its parent drug, it targets bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidation. It has antimicrobial effects against Gram-positive and Gram-negative bacteria, including many veterinary isolates, and shares the same mechanism of action as other cephalosporins.
|
|---|---|
| ln Vitro |
Desfuroylceftiofur is active against 539 veterinary isolates of Gram-negative bacteria and Gram-positive cocci bacteria (MIC50s = 0.0078-1 and 0.015-4 ug/ml, respectively). It is the key active moiety responsible for the antibacterial activity observed in vivo following ceftiofur administration, and the main target for residue detection.
|
| ln Vivo |
As the major active metabolite, its in vivo activity is directly related to the efficacy of ceftiofur. It is responsible for the therapeutic effects in livestock (cattle, pigs, horses) against respiratory and other bacterial infections. Its formation in the body correlates with the clearance of ceftiofur and the duration of the antibacterial effect, making it a key marker for pharmacokinetic and residue studies.
|
| Enzyme Assay |
For a cell-free biochemical assay (e.g., measuring PBP binding), bacterial membranes isolated from E. coli are incubated with a fluorescent penicillin derivative (e.g., Bocillin FL) and varying concentrations of desfuroylceftiofur (0.1-100 ug/mL) for 30 min at 37degC. Proteins are resolved by SDS-PAGE, and the fluorescence is detected to assess the displacement of Bocillin FL from PBPs. The inhibition of PBP binding is quantified to determine the IC50.
|
| Cell Assay |
For in vitro susceptibility testing, bacterial isolates are grown overnight in Mueller-Hinton broth. A standardized inoculum (5x10^5 CFU/mL) is added to 96-well plates containing serial two-fold dilutions of desfuroylceftiofur (0.008-16 ug/mL). The plates are incubated at 37degC for 18-24 hours. The MIC is determined as the lowest concentration that visually inhibits bacterial growth. Controls include growth without drug and a ceftiofur standard for comparison.
|
| Animal Protocol |
A typical in vivo animal study for residue monitoring involves administering ceftiofur to cattle (e.g., 1 mg/kg subcutaneously) once daily for 3-5 days. At various withdrawal times (e.g., 0, 1, 3, 5, 7, 10 days post-dose), tissue samples (kidney, liver, muscle) are collected. Desfuroylceftiofur concentrations are measured by HPLC-MS/MS after derivatization (e.g., with iodoacetamide) to stabilize the reactive thiol group. The withdrawal period is determined by the time it takes for residues to fall below the established maximum residue limit (MRL).
|
| ADME/Pharmacokinetics |
Desfuroylceftiofur has a molecular weight of 429.49 g/mol and a chemical formula of C14H15N5O5S3. As a bioactive metabolite, it is less stable than the parent drug due to the free thiol group. It is typically derivatized to the stable acetamide form for detection. The compound has very limited bioavailability if administered directly, which is why ceftiofur is administered as a prodrug.
|
| Toxicity/Toxicokinetics |
Toxicity and resistance profile mirrors that of ceftiofur. As a metabolite, there are no unique toxicities. The primary concern in food animals is the withdrawal period to ensure no drug residues remain in meat or milk. For laboratory use, standard safety precautions for handling antibiotics should be observed. Avoid contact with skin and eyes.
|
| Additional Infomation |
Desfuroylceftiofur is the major metabolite of ceftiofur in all target species (cattle, pigs, sheep, goats, chickens). The United States Food and Drug Administration (FDA) has established a safe level/tolerance for residues of desfuroylceftiofur in edible tissues. It is used as the marker residue for regulatory compliance testing of ceftiofur in food-producing animals.
|
| Molecular Formula |
C14H15N5O5S3
|
|---|---|
| Molecular Weight |
429.4944
|
| Exact Mass |
429.024
|
| CAS # |
120882-22-6
|
| PubChem CID |
5487205
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.89g/cm3
|
| Melting Point |
>200ºC(dec)
|
| Index of Refraction |
1.859
|
| LogP |
0.654
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
730
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CO/N=C(\C(NC1C(=O)N2C(=C(CSC12)CS)C(=O)O)=O)/C1=CSC(N)=N1
|
| InChi Key |
OITCOWCNESRWSM-GHXIOONMSA-N
|
| InChi Code |
InChI=1S/C14H15N5O5S3/c1-24-18-7(6-4-27-14(15)16-6)10(20)17-8-11(21)19-9(13(22)23)5(2-25)3-26-12(8)19/h4,8,12,25H,2-3H2,1H3,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
|
| Chemical Name |
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(sulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3283 mL | 11.6417 mL | 23.2834 mL | |
| 5 mM | 0.4657 mL | 2.3283 mL | 4.6567 mL | |
| 10 mM | 0.2328 mL | 1.1642 mL | 2.3283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
